| Sep 18 2024 |
Blank Rome State of the Cannabis Industry Panelist Interview Series: James Daley, Needham Bank Senior Vice President and Director Structured Finance |
Blank Rome LLP |
| Sep 18 2024 |
Health Canada Finalizes Brominated Vegetable Oil Ban |
Keller and Heckman LLP |
| Sep 18 2024 |
California Bans Most Hemp Products and Illuminates Battle Between Hemp and Marijuana Businesses |
Bradley Arant Boult Cummings LLP |
| Sep 18 2024 |
Four Strategies and Five Legal Arguments To Defend Your Company Against EPA’s Benzene Enforcement Initiative |
Beveridge & Diamond PC |
| Sep 18 2024 |
A Study in THC-O: Unpacking the Recent Anderson Case |
Norris McLaughlin P.A. |
| Sep 17 2024 |
Ubrelvy Untitled Letter – A Double Fault for AbbVie? Or Makeup Misread for FDA? |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 17 2024 |
Will Sustained Pressure on the 340B Program Finally Lead to Much Needed Reform? |
Mintz |
| Sep 17 2024 |
FDA and the Fountain of Youth: Regulatory Hurdles in the Longevity Biotech Community |
Womble Bond Dickinson (US) LLP |
| Sep 17 2024 |
Celanese v. ITC: How the On-Sale Bar Can Turn Sweet Sales into Spoiled Patents |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 17 2024 |
August 2024 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |
| Sep 17 2024 |
Foggy Roads and Auto Accidents: Navigating Liability in Foggy Weather |
Buckfire Law |
| Sep 17 2024 |
The 340B Drug Pricing Program: Top Five Things to Know |
Foley & Lardner LLP |
| Sep 17 2024 |
NCC Requests Extra Time to Comment on FSIS Salmonella Rule |
Keller and Heckman LLP |
| Sep 16 2024 |
U.S. House Of Representatives Passes The BIOSECURE Act During “China Week” |
Squire Patton Boggs (US) LLP |
| Sep 16 2024 |
Understanding Preliminary Injunction: A Review of a Recent Federal Circuit Decision |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 16 2024 |
Cannabis and Civil Litigation: Has the Cannabis Industry Finally Met Its Most Dangerous Foe? |
Bradley Arant Boult Cummings LLP |
| Sep 13 2024 |
Federal Circuit Says No Timing Requirement to Qualify as A POSITA |
Foley & Lardner LLP |
| Sep 13 2024 |
McDermott+ Check-Up: September 13, 2024 |
McDermott Will & Emery |
| Sep 13 2024 |
USDA and CDFA Declare California Free of Invasive Fruit Flies |
Keller and Heckman LLP |
| Sep 12 2024 |
IARC Releases Its Priority Evaluation List for 2025-2029 |
Nelson Mullins |
| Sep 12 2024 |
U.S. Chamber of Commerce Releases Report Examining Impact of Essential Fluorochemistries |
Bergeson & Campbell, P.C. |
| Sep 12 2024 |
NIOSH Blog Item Highlights NTRC’s Toxicology and Internal Dose Team |
Bergeson & Campbell, P.C. |
| Sep 12 2024 |
Blank Rome State of the Cannabis Industry Panelist Interview Series: Patrick Kim, Altmore Capital Co-Founder and Managing Director |
Blank Rome LLP |
| Sep 12 2024 |
Back to the Future: Expert Can Be Skilled Artisan Based on Later-Acquired Knowledge |
McDermott Will & Emery |
| Sep 11 2024 |
Registration Opens for NNI Webinar on Nanometrology for Continuous and Automated Manufacturing |
Bergeson & Campbell, P.C. |
| Sep 11 2024 |
California Legislature Passes Bill Requiring Fortification of Corn Masa with Folic Acid |
Keller and Heckman LLP |
| Sep 11 2024 |
Federal Appeals Court: Pay That Man His Money, Unless That Money Is Illegal Marijuana Money |
Bradley Arant Boult Cummings LLP |
| Sep 11 2024 |
300 Days Since Biden’s AI Executive Order: What Have Federal Agencies Accomplished and What is on the Horizon? |
Squire Patton Boggs (US) LLP |
| Sep 11 2024 |
Petitions Filed to Add Several Chemicals to List of Taxable Substances; Comments Due November 4, 2024 |
Bergeson & Campbell, P.C. |
| Sep 11 2024 |
This Week in 340B: September 3 – 9, 2024 |
McDermott Will & Emery |
| Sep 10 2024 |
NIFA Announces $5.3 Million Investment in Biotechnology Risk Assessment Research |
Bergeson & Campbell, P.C. |
| Sep 10 2024 |
FDA Rejects MDMA Treatment for PTSD; Setbacks and New Directions |
Womble Bond Dickinson (US) LLP |
| Sep 10 2024 |
FSIS Updates Guidance for Animal-Raising and Environmental Claims |
Keller and Heckman LLP |
| Sep 10 2024 |
BIOSECURE Act: Anticipated Movement, Key Provisions, and Likely Impact |
Foley & Lardner LLP |
| Sep 9 2024 |
Challenges in AI-Enabled Biomarker Discovery |
Foley & Lardner LLP |
